InsidersTradesSigma
GSK plc Stock: price and management transactions · United Kingdom · RNS (LSE)
Follow the GSK plc stock price and the full directors' dealings record of the company, a publicly traded company based in United Kingdom. Shares are listed on UK GB, under the supervision of RNS (LSE). Operating in the Healthcare & Pharma sector, GSK plc has recorded 1,517 reports. Market capitalisation: €78.5bn. The latest transaction was filed on 10 July 2026 (Purchase). Among the most active insiders: Maya Martinez-Davis. All data is free.
GSK plc, listed on the XLON market in the Healthcare & Pharma sector, reported a total of 121 insider trading declarations in the past 90 days. The total amount of insider purchases was approximately 670,513 EUR, with no sales recorded. The top insiders included Dr H al Barron, a Non-Executive Director, who made two purchases totaling about 130,907 EUR. Charles Bancroft, Senior Independent Non-Executive Director, had three purchases amounting to approximately 109,638 EUR. Wendy Becker, also an Independent Non-Executive Director, made one purchase totaling about 90,608 EUR. Other notable purchases on June 24, 2026, included Dr Vishal Sikka, Dr Jeannie Lee, Elizabeth (Liz) McKee Anderson, Dr Anne Beal, and Dr Hal Dietz, with amounts ranging from approximately 39,957 EUR to 73,942 EUR. Additionally, Julie Brown, Chief Financial Officer, had a vesting declaration of about 38,719 EUR on April 16, 2026.
Auto-generated summary, refreshed daily.Updated today
1,517
Insider Decl.
0
Thresholds
€3m
1031 ops.
Buy Volume
€54m
124 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate GSK plc Hold (neutral), based on 19 analysts. Average price target: £2,116.90.
40Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 2,147 of 25,973 companies
75.3
score / 100
Value70
Quality81
FCF yld6.1%
Earn yld7.3%
EV/EBITDA9.2x
ROE41%
Gross mgn72%
Net mgn17%
Debt/EBITDA1.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 10 July 2026
Declarations1,517 total
0New York Stock Exchange (XNYS)RNS:9661747
Ideal exit: 3 Apr 2027 (T+270)
0New York Stock Exchange (XNYS)RNS:289d903e-7ee1-4fa9-bcbd-3a43dc019bc2
Ideal exit: 3 Apr 2027 (T+270)
0New York Stock Exchange (XNYS)RNS:9635096
Ideal exit: 19 Mar 2027 (T+270)
0New York Stock Exchange (XNYS)RNS:f96aec1d-517b-42fe-998e-999eab24c64e
Ideal exit: 19 Mar 2027 (T+270)
1,550 shares@ £19.35240.0000% mcap7.4% of flowLondon Stock Exchange (XLON)RNS:9632737-0
Ideal exit: 16 Mar 2027 (T+270)
789 shares@ £50.69080.0001% mcap96.7% of flowNew York Stock Exchange (XNYS)RNS:9632737-1
Ideal exit: 19 Mar 2027 (T+270)
1,855 shares@ £50.69080.0001% mcap84.1% of flowNew York Stock Exchange (XNYS)RNS:9632737-2
Ideal exit: 19 Mar 2027 (T+270)
745 shares@ £50.69080.0001% mcap94.8% of flowNew York Stock Exchange (XNYS)RNS:9632737-3
Ideal exit: 19 Mar 2027 (T+270)
667 shares@ £50.69080.0001% mcap95.3% of flowNew York Stock Exchange (XNYS)RNS:9632737-4
Ideal exit: 19 Mar 2027 (T+270)
802 shares@ £50.69080.0001% mcap96.8% of flowNew York Stock Exchange (XNYS)RNS:9632737-5
Ideal exit: 19 Mar 2027 (T+270)
1,266 shares@ £50.69080.0001% mcap92.1% of flowNew York Stock Exchange (XNYS)RNS:9632737-6
Ideal exit: 19 Mar 2027 (T+270)
1,550 shares@ £19.35240.0000% mcap8.0% of flowLondon Stock Exchange (XLON)RNS:1cabaef6-2e05-4f58-a412-24a2f7509642-0
Ideal exit: 16 Mar 2027 (T+270)
789 shares@ £0.50690.0000% mcap29.1% of flowNew York Stock Exchange (XNYS)RNS:1cabaef6-2e05-4f58-a412-24a2f7509642-1
Ideal exit: 19 Mar 2027 (T+270)
1,855 shares@ £0.50690.0000% mcap5.3% of flowNew York Stock Exchange (XNYS)RNS:1cabaef6-2e05-4f58-a412-24a2f7509642-2
Ideal exit: 19 Mar 2027 (T+270)
745 shares@ £0.50690.0000% mcap18.1% of flowNew York Stock Exchange (XNYS)RNS:1cabaef6-2e05-4f58-a412-24a2f7509642-3
Ideal exit: 19 Mar 2027 (T+270)
667 shares@ £0.50690.0000% mcap20.4% of flowNew York Stock Exchange (XNYS)RNS:1cabaef6-2e05-4f58-a412-24a2f7509642-4
Ideal exit: 19 Mar 2027 (T+270)
802 shares@ £0.50690.0000% mcap30.2% of flowNew York Stock Exchange (XNYS)RNS:1cabaef6-2e05-4f58-a412-24a2f7509642-5
Ideal exit: 19 Mar 2027 (T+270)
1,266 shares@ £0.50690.0000% mcap11.7% of flowNew York Stock Exchange (XNYS)RNS:1cabaef6-2e05-4f58-a412-24a2f7509642-6
Ideal exit: 19 Mar 2027 (T+270)
14 shares@ £18.83930.0000% mcap0.0% of flowLondon Stock Exchange (XLON)RNS:9614374-5
Ideal exit: 6 Mar 2027 (T+270)
14 shares@ £18.83930.0000% mcap0.0% of flowLondon Stock Exchange (XLON)RNS:9614374-6
Ideal exit: 6 Mar 2027 (T+270)
12 shares@ £18.83920.0000% mcap0.0% of flowLondon Stock Exchange (XLON)RNS:9614374-7
Ideal exit: 6 Mar 2027 (T+270)
14 shares@ £18.83930.0000% mcap0.0% of flowLondon Stock Exchange (XLON)RNS:9614374-0
Ideal exit: 6 Mar 2027 (T+270)
14 shares@ £18.83930.0000% mcap0.0% of flowLondon Stock Exchange (XLON)RNS:9614374-1
Ideal exit: 6 Mar 2027 (T+270)
14 shares@ £18.83930.0000% mcap0.0% of flowLondon Stock Exchange (XLON)RNS:9614374-2
Ideal exit: 6 Mar 2027 (T+270)
14 shares@ £18.83930.0000% mcap0.0% of flowLondon Stock Exchange (XLON)RNS:9614374-3
Ideal exit: 6 Mar 2027 (T+270)
25 of 1517 declarations
About GSK plc
GSK plc is a major global biopharmaceutical group listed on the London Stock Exchange (FTSE 100/250/AIM) and domiciled in the United Kingdom. The company traces its roots to the long history of GlaxoSmithKline, but in recent years it has been reshaped into a more focused biopharma business following the separation of its consumer healthcare arm. GSK is headquartered in London and now reports under two operating segments: Commercial Operations and Total R&D. Commercial Operations is further organised into three product groups: Vaccines, Specialty Medicines and General Medicines. This structure highlights a business model centred on scientific innovation, intellectual property protection and the extension of the commercial life of key therapies. From a competitive standpoint, GSK is one of the leading players in vaccines and in several specialist therapeutic areas. Its portfolio is particularly strong in respiratory diseases, immunology, oncology and HIV. The group combines a broad commercial base with a differentiated product mix, underpinned by substantial research and development capabilities and an international manufacturing footprint. In 2024, the vast majority of turnover was generated outside the UK, with the United States representing the largest market, followed by the rest of the world and Europe, underscoring GSK’s status as a geographically diversified global healthcare company. In terms of products and services, GSK sells vaccines, specialty medicines and general medicines. Its strategy is increasingly shaped by pipeline innovation, targeted acquisitions and disciplined capital allocation. Recent developments reinforce this direction: the completion of the acquisition of 35Pharma Inc. in 2025, continued interest in selective external growth opportunities, an agreement with the U.S. government aimed at lowering prices and broadening access to respiratory medicines, and a major planned investment in U.S. R&D and manufacturing infrastructure. The company’s 2025 performance updates also pointed to strong operating momentum, especially in Specialty Medicines, with double-digit growth in Respiratory Inflammation & Immunology, Oncology and HIV. For investors, GSK offers the profile of a large-cap defensive pharmaceutical company with global cash-generating commercial franchises and growth optionality from pipeline development and bolt-on acquisitions. In the context of the London Stock Exchange (FTSE 100/250/AIM) in the United Kingdom, it remains a high-quality healthcare name balancing scale, innovation, and regulatory or competitive risks inherent to the sector.
